Cosentyx's Target and Mechanism
Cosentyx (secukinumab) is a monoclonal antibody that binds to interleukin-17A (IL-17A), a key cytokine driving inflammation in autoimmune diseases like psoriasis and psoriatic arthritis. By neutralizing IL-17A, it disrupts signaling pathways in local immune cells, reducing their activation at inflammation sites such as skin or joints.[1]
How It Blocks Immune Cell Activation Locally
IL-17A normally amplifies local inflammation by:
- Stimulating keratinocytes and fibroblasts to produce chemokines (e.g., CXCL1, CXCL8), which recruit neutrophils and T cells.
- Promoting Th17 cell differentiation and survival, creating a feedback loop of pro-inflammatory cytokines like IL-6 and TNF-α.
Cosentyx halts this by:
1. Directly sequestering IL-17A, preventing it from binding to IL-17 receptors (IL-17RA/RC) on target cells.
2. Reducing downstream NF-κB and MAPK pathway activation in dendritic cells, macrophages, and endothelial cells, which cuts chemokine production and immune cell migration to affected tissues.
3. Lowering local Th17 cell numbers and activity, as IL-17A sustains their function.
This leads to rapid symptom relief—skin clearance in psoriasis often starts within a week—by dampening the inflammatory cascade without broad immunosuppression.[2][3]
Effects on Specific Local Immune Cells
- Neutrophils: Fewer recruited due to reduced chemokines; less oxidative burst and tissue damage.
- Th17 Cells: Inhibited expansion and cytokine release (IL-17, IL-22), breaking the autoimmune loop.
- Dendritic Cells and Macrophages: Diminished antigen presentation and IL-23 production, which otherwise fuels Th17 responses.
- Keratinocytes: Less proliferation and antimicrobial peptide expression, normalizing skin barrier function.
Clinical studies show IL-17A blockade shrinks local infiltrates in psoriatic plaques, with biopsies confirming fewer activated CD4+ T cells and neutrophils.[4]
Does It Affect Systemic Immunity?
Cosentyx acts primarily locally due to subcutaneous dosing and high tissue penetration at inflammation sites, sparing circulating immune cells. Infection rates remain low compared to broader immunosuppressants, though candidiasis risk rises slightly from IL-17's antifungal role.[5]
Comparison to Other Biologics
Unlike TNF inhibitors (e.g., Humira), which broadly suppress multiple cytokines, Cosentyx targets the IL-17 pathway downstream, offering faster skin responses but less joint efficacy in some rheumatoid cases. IL-23 inhibitors (e.g., Tremfya) act upstream on Th17 differentiation, providing similar local effects with potentially longer remission.[6]
[1]: Novartis. Cosentyx Prescribing Information. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[2]: Langley RG et al. (2014). N Engl J Med. Secukinumab in plaque psoriasis.
[3]: Papp KA et al. (2013). N Engl J Med. Phase 3 trial of secukinumab.
[4]: Chiricozzi A et al. (2016). J Invest Dermatol. IL-17 blockade effects on skin immune cells.
[5]: McInnes IB et al. (2015). Ann Rheum Dis. Safety profile.
[6]: Griffiths CE et al. (2015). Lancet. IL-17 vs IL-23 inhibitors in psoriasis.